The Economic Impact of the Introduction of Biosimilars in Inflammatory Bowel Disease.
about
The Rituximab Biosimilar CT-P10 in Rheumatology and Cancer: A Budget Impact Analysis in 28 European CountriesTrends in medicines procurement by the Brazilian federal government from 2006 to 2013.The nocebo effect challenges the non-medical infliximab switch in practice.Path of Interchangeability of Biosimilars in Pediatric Inflammatory Bowel Disease: Quality Before Cost Savings.
P2860
The Economic Impact of the Introduction of Biosimilars in Inflammatory Bowel Disease.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
The Economic Impact of the Introduction of Biosimilars in Inflammatory Bowel Disease.
@en
type
label
The Economic Impact of the Introduction of Biosimilars in Inflammatory Bowel Disease.
@en
prefLabel
The Economic Impact of the Introduction of Biosimilars in Inflammatory Bowel Disease.
@en
P2093
P2860
P356
P1476
The Economic Impact of the Introduction of Biosimilars in Inflammatory Bowel Disease.
@en
P2093
A A van Bodegraven
B Oldenburg
P D Siersema
initiative of Crohn’s and Colitis
P2860
P304
P356
10.1093/ECCO-JCC/JJW153
P577
2016-08-29T00:00:00Z